GeneHealth - Your precision medicine

Wolfram Syndrome 2

Disease Details

Family Health Simplified

Buy Membership

Description: Wolfram syndrome 2 is a rare genetic disorder characterized by diabetes insipidus, diabetes mellitus, optic atrophy, and deafness, along with several other neurological and systemic complications. It is caused by mutations in the CISD2 gene.
Type: Wolfram Syndrome 2 is transmitted in an autosomal recessive manner.
Signs And Symptoms: Wolfram syndrome 2 (WS2) is a rare genetic disorder. The signs and symptoms typically include:

1. **Diabetes Insipidus**: This leads to an imbalance of fluids in the body, causing excessive thirst and urination.
2. **Diabetes Mellitus**: Usually appears in childhood or adolescence and is insulin-dependent.
3. **Optic Atrophy**: Progressive vision loss due to the degeneration of the optic nerves.
4. **Hearing Loss**: Sensorineural hearing impairment.
5. **Neurological Symptoms**: These may include issues with balance and coordination, speech difficulties, and peripheral neuropathy.
6. **Urological Problems**: Such as bladder dysfunction.
7. **Psychiatric Manifestations**: Depression and other psychiatric issues are also common.

These symptoms typically emerge in childhood or early adulthood and progressively worsen over time.
Prognosis: The first symptom is typically diabetes mellitus, which is usually diagnosed around the age of 6. The next symptom to appear is often optic atrophy, the wasting of optic nerves, around the age of 11. The first signs of this are loss of colour vision and peripheral vision. The condition worsens over time, and people with optic atrophy are usually blind within 8 years of the first symptoms. Life expectancy of people suffering from this syndrome is about 30 years.
Onset: Wolfram syndrome 2 typically has an onset in childhood or early adulthood.
Prevalence: The prevalence of Wolfram Syndrome 2 is not well-documented, but it is considered to be extremely rare. As with other forms of Wolfram Syndrome, it is a genetic disorder characterized by a range of symptoms including diabetes insipidus, diabetes mellitus, optic atrophy, and deafness.
Epidemiology: Wolfram Syndrome 2 is an extremely rare genetic disorder, and detailed epidemiological data is not well-established due to its scarcity. Generally, Wolfram Syndrome (WS) as a whole, including both types 1 and 2, has an estimated prevalence of approximately 1 in 500,000 to 1 in 770,000 individuals worldwide. Wolfram Syndrome 2 is even rarer than type 1, and thus specific prevalence and incidence rates are not readily available. The disease affects both males and females without racial or ethnic predilections.
Intractability: Wolfram syndrome 2 (WFS2) is currently considered intractable, as there is no cure or highly effective treatment available. Management focuses on symptomatic relief and supportive care to address complications such as diabetes mellitus, hearing loss, and neurodegenerative issues.
Disease Severity: Wolfram syndrome 2 (WFS2) is generally characterized by a severe and progressive course. The severity can vary among individuals but typically includes diabetes mellitus, optic atrophy, and neurological complications. The condition can lead to significant disability and a reduced life expectancy.
Healthcare Professionals: Disease Ontology ID - DOID:0110630
Pathophysiology: Wolfram Syndrome 2 (WFS2) is a rare genetic disorder characterized by neurodegeneration and endocrine abnormalities. It results from mutations in the CISD2 gene, which plays a role in mitochondrial function. CISD2 mutations impair mitochondrial integrity and lead to cell death, particularly affecting insulin-producing pancreatic beta cells and neuronal cells. This causes a range of symptoms including diabetes mellitus, optic atrophy, and neurological deficits.
Carrier Status: Carrier status refers to the condition in which an individual carries one copy of a mutated gene that, when present in two copies, causes a specific genetic disorder. For Wolfram syndrome 2, being a carrier typically means that the person has one mutated copy of the gene and one normal copy. Carriers usually do not show symptoms of the syndrome but can pass the mutated gene to their offspring.

"NAN" (not a number) might imply missing data or a non-applicable status, but in this context, it is not a relevant term for discussing carrier status.
Mechanism: Wolfram syndrome type 2 (WFS2) is a rare genetic disorder characterized by symptoms such as diabetes insipidus, diabetes mellitus, optic atrophy, and deafness. The disease mechanism primarily involves mutations in the CISD2 gene. CISD2 encodes a protein that is localized to the mitochondria-associated membrane, playing a crucial role in maintaining mitochondrial function and integrity.

Molecular mechanisms underlying WFS2 involve disruptions caused by CISD2 mutations, which impair mitochondrial function leading to cellular stress and apoptosis. This mitochondrial dysfunction contributes to the degeneration of neurons and pancreatic beta cells, which are highly energy-dependent, thereby manifesting in the clinical symptoms of WFS2. The exact pathways are still being elucidated, but the link between CISD2 mutations and mitochondrial impairment is well established.
Treatment: There is no known direct treatment. Current treatment efforts focus on managing the complications of Wolfram syndrome, such as diabetes mellitus and diabetes insipidus. However a number of symptoms can be managed to improve quality of life. These include: insulin for diabetes alongside other medications for this. Desmopressin to treat diabetes insipidus, antibiotics for UTI, hearing aids of cochlear implants for hearing loss and supportive aids for visual loss such as magnifying glasses. New treatment advances include research evaluating ER calcium stabilizers and repurposed drugs/small molecules to reduce ER stress and reduce apoptosis, thus slowing progression of Wolfram syndrome.A three tiered approach toward the treatment of Wolfram syndrome includes stopping disease progression, protecting and regrowing remaining tissue, and replacing and repairing pathogenic genes.
Compassionate Use Treatment: Wolfram Syndrome 2 (WFS2) is a rare genetic disorder characterized by various symptoms, including diabetes insipidus, diabetes mellitus, optic atrophy, and deafness. Regarding compassionate use treatments and off-label or experimental treatments:

1. **Compassionate Use Treatment:**
- This can involve investigational drugs or treatments not yet approved for general use. Patients with WFS2 might have access to certain experimental drugs through compassionate use programs, although each case must be evaluated individually.

2. **Off-Label or Experimental Treatments:**
- **GLP-1 Receptor Agonists:** Originally developed for diabetes mellitus, these might be studied for their potential neuroprotective effects in WFS2.
- **Dantrolene:** Typically used for muscle spasticity, Dantrolene has been researched for its potential to protect against cellular stress and apoptosis in conditions like WFS2.
- **Chemical Chaperones:** These can help in protein folding and have the potential to alleviate endoplasmic reticulum stress, which is a known issue in WFS2.

Because Wolfram Syndrome 2 is rare, specific treatments are often based on managing the broad spectrum of symptoms rather than targeting the syndrome directly. Always consult a medical professional for the most current and personalized treatment options.
Lifestyle Recommendations: For Wolfram Syndrome 2 (WFS2), lifestyle recommendations typically involve symptom management and supportive care, as it is a rare and progressive genetic disorder affecting multiple organ systems. Here are some general recommendations:

1. **Regular Monitoring**: Frequent medical check-ups with a multidisciplinary team, including endocrinologists, ophthalmologists, audiologists, and neurologists to monitor the progression of the disease.

2. **Blood Sugar Management**: Patients often develop diabetes mellitus; therefore, maintaining strict blood sugar control through diet, exercise, and medication is crucial.

3. **Vision and Hearing Care**: Regular eye and ear exams to monitor vision and hearing loss, with corrective devices such as glasses, hearing aids, or cochlear implants as needed.

4. **Psychological Support**: Counseling and psychological support to help cope with the emotional and mental health aspects of living with a chronic disease.

5. **Diet and Nutrition**: A balanced diet tailored to manage diabetes and other metabolic complications, ideally under the guidance of a nutritionist.

6. **Exercise**: Regular physical activity to maintain overall health, improve cardiovascular fitness, and manage blood sugar levels, while being mindful of any physical limitations.

7. **Education and Employment**: Consideration of special education services and vocational training to support academic and career goals.

8. **Assistive Technologies**: Utilization of devices and technologies that aid in daily living, communication, and mobility.

9. **Symptom Management**: Addressing specific symptoms such as bladder dysfunction or neuropathy with appropriate medical interventions.

10. **Community and Family Support**: Engaging with support groups and seeking assistance from family and community resources to improve quality of life.

Coordination with healthcare providers to create a personalized care plan is essential for managing Wolfram Syndrome 2 effectively.
Medication: Wolfram syndrome 2 is a rare genetic disorder for which treatment primarily focuses on managing the symptoms rather than addressing the underlying cause. Unfortunately, there are no specific medications available to treat Wolfram syndrome 2 itself. Instead, treatment may include:

1. **Diabetes management**: Insulin therapy to control blood sugar levels.
2. **Amelioration of neurological symptoms**: Medication for conditions such as epilepsy or spasticity if they occur.
3. **Support for vision and hearing loss**: Use of hearing aids and visual aids.

It's critical for individuals with Wolfram syndrome 2 to have a tailored treatment plan coordinated by a specialist familiar with the disorder. Research is ongoing to find more targeted therapies.
Repurposable Drugs: For Wolfram syndrome 2, there are currently no widely recognized repurposable drugs specifically targeting this disorder. Research is ongoing, and therapeutic strategies are continually being explored, but as of now, no definitive repurposable medications have been established for effective management or treatment.
Metabolites: Wolfram Syndrome 2 (WFS2) is a rare genetic disorder characterized by a combination of diabetes insipidus, diabetes mellitus, optic atrophy, and deafness. Metabolites associated with Wolfram Syndrome 2 have not been as extensively studied or characterized as those for more common conditions, resulting in limited specific metabolic information. Often, metabolic abnormalities can be inferred from the symptoms, such as disruptions in glucose metabolism due to diabetes mellitus. However, detailed metabolomic profiles specific to WFS2 are not widely documented in existing scientific literature.
Nutraceuticals: There is currently no well-established evidence that nutraceuticals have a significant impact on Wolfram Syndrome 2. This rare genetic disorder, which typically involves diabetes insipidus, diabetes mellitus, optic atrophy, and deafness, is mainly managed through symptom-specific treatments. Research efforts are ongoing, but no specific nutraceuticals have been validated for modifying the disease's course. It's essential to consult healthcare providers for personalized advice and treatment options.
Peptides: For Wolfram Syndrome 2 (WFS2), there is no specific information linking it directly to peptides or nanotechnology in current research and therapeutic approaches. WFS2 is a rare genetic disorder characterized by diabetes insipidus, diabetes mellitus, optic atrophy, and deafness. It is caused by mutations in the CISD2 gene. Treatment is primarily symptomatic and supportive, focusing on managing the individual symptoms.